Publications

MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.

Calura E

Clin Cancer Res. 2013 Jun 13;19(15):4114-23. doi: 10.1158/1078-0432.CCR-13-0360

Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Marchini S

Eur J Cancer. 2012 Aug 13;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026

Mode of action of trabectedin in myxoid liposarcomas.

Di Giandomenico S

Oncogene. 2013 Nov 11;33(44):5201-10. doi: 10.1038/onc.2013.462

Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.

Beltrame L

Ann Oncol. 2015 Apr 6;26(7):1363-71. doi: 10.1093/annonc/mdv164

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.

Giordano S

Sci Rep. 2016 Dec 21;6:39284. doi: 10.1038/srep39284

Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.

Petrillo M

Ann Oncol. 2016 Jan 17;27(4):625-34. doi: 10.1093/annonc/mdw007

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Vázquez R

Int J Cancer. 2016 Sep 19;140(1):197-207. doi: 10.1002/ijc.30412

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.

Belgiovine C

Br J Cancer. 2017 Jul 6;117(5):628-638. doi: 10.1038/bjc.2017.205

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.

Colombo N

Br J Cancer. 2019 Sep 20;121(9):744-750. doi: 10.1038/s41416-019-0584-5

Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.

Frapolli R

Clin Cancer Res. 2019 Sep 3;25(24):7565-7575. doi: 10.1158/1078-0432.CCR-19-0976